Bio-Techne Corporation or Viking Therapeutics, Inc.: Who Manages SG&A Costs Better?

SG&A Cost Management: Bio-Techne vs. Viking Therapeutics

In the competitive landscape of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Bio-Techne Corporation and Viking Therapeutics, Inc. offer a fascinating case study in this regard. Over the past decade, Bio-Techne has consistently managed higher SG&A expenses, peaking at approximately $397 million in 2024. In contrast, Viking Therapeutics, with a more modest SG&A expenditure, reached its highest at around $37 million in 2023. This stark difference highlights Bio-Techne's expansive operational scale compared to Viking's more streamlined approach. Interestingly, while Bio-Techne's SG&A expenses grew by over 550% from 2014 to 2024, Viking's expenses increased by nearly 2,900% in the same period, reflecting its rapid growth phase. This data underscores the diverse strategies employed by biotech firms in managing operational costs, with Bio-Techne focusing on scale and Viking on agility.